Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and
non-malignant diseases, and in paediatric patients older than one month with malignant diseases.
It is available in the following presentation:
Trecondi 1 g powder for solution for infusion:
One vial contains 1 g of treosulfan
Trecondi 5 g powder for solution for infusion:
One vial contains 5 g of treosulfan.
Trecondi is distributed in Ireland by Fannin Ltd in partnership with Medac (This link will take you to a non-Fannin Ltd. website. Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.)
For a copy of the SPC please click here.
Method of Sale: POM
EU/1/18/1351/001 (1 g, 1 vial)
EU/1/18/1351/002 (1 g, 5 vials)
EU/1/18/1351/003 (5 g, 1 vial)
EU/1/18/1351/004 (5 g, 5 vials)
MAH Holder: medac, Gesellschaft für klinische Spezialpräparate mbH, Theaterstr. 622880 Wedel, Germany
Additional information available on request.
Date of preparation: April 2020